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1. INTRODUCTION {#jcmm14696-sec-0001}
===============

Osteoarthritis (OA) is the most prevalent chronic joint disease that contributes to cartilage matrix degradation.[1](#jcmm14696-bib-0001){ref-type="ref"} Major mechanism of OA is characterized by abnormal joint tissue metabolism and results in cartilage degradation, bone remodelling, joint inflammation, osteophyte formation and loss of normal joint function.[2](#jcmm14696-bib-0002){ref-type="ref"} About 9.6% of men and 18% of women ≥ 60 years old suffer from symptomatic OA worldwide.[3](#jcmm14696-bib-0003){ref-type="ref"} Multiple factors, including advanced age, excessive body weight, repeated trauma or surgery to the joint structures, diabetes and hormone‐related disorders, contribute to increased risk of OA.[4](#jcmm14696-bib-0004){ref-type="ref"} Studies provide clear evidence of a heritable component in susceptibility of OA,[2](#jcmm14696-bib-0002){ref-type="ref"}, [5](#jcmm14696-bib-0005){ref-type="ref"}, [6](#jcmm14696-bib-0006){ref-type="ref"} but the specific genetic factors are largely unknown. It therefore remains a challenge to identify risk alleles or candidate genes that contribute to OA pathogenesis.

The Wnt/β‐catenin signalling pathway plays a crucial role in the regulation, proliferation, differentiation and cellular death processes in numerous anomalies of development, growth and homeostasis in animal organisms.[7](#jcmm14696-bib-0007){ref-type="ref"} We previously found the Wnt/β‐catenin pathway plays a key role in OA by inducing the expression of matrix metalloproteinases.[8](#jcmm14696-bib-0008){ref-type="ref"} Besides, it contributes to cell differentiation and apoptosis and directly regulates chondrocyte phenotype.[9](#jcmm14696-bib-0009){ref-type="ref"}, [10](#jcmm14696-bib-0010){ref-type="ref"} Once Wnt protein is secreted, it binds to the frizzled receptor and low‐density lipoprotein receptor‐related protein 5/6 (LRP5/6) in order to stabilize the β‐catenin protein and initiate an intricate signalling cascade.[11](#jcmm14696-bib-0011){ref-type="ref"}

Abnormal activation of the Wnt/β‐catenin signalling is involved in the OA pathology, but little is known about the association of the Wnt pathway‐related gene polymorphisms with OA susceptibility. Thus, this hospital‐based case‐control study was conducted to investigate the effects of Wnt pathway‐related genes (DVL1, WNT16, ITIH5, LRP1 and SFRP1) polymorphisms on the risk of OA in a Chinese population.

2. MATERIALS AND METHODS {#jcmm14696-sec-0002}
========================

2.1. Search strategy {#jcmm14696-sec-0003}
--------------------

We systematically searched the Pubmed and EMBASE databases up to 12 January 2019 to identify eligible studies using the following keywords: 'osteoarthritis', 'OA', 'wnt signalling pathway', 'Wnt/β‐catenin signalling pathway', 'polymorphism', 'SNP' and 'variant'. We also checked references in eligible studies and reviews for other relevant studies. No restriction was set on language or ethnicity.

2.2. Protein‐protein interaction network and functional annotation {#jcmm14696-sec-0004}
------------------------------------------------------------------

We constructed protein‐protein interaction (PPI) network to identify significant interactions among proteins encoded by Wnt pathway‐related genes using the search tool STRING (<http://string-db.org/>).[12](#jcmm14696-bib-0012){ref-type="ref"} PPI network was constructed by the PPI pairs with protein interaction scores exceeding 0.4. Gene Ontology (GO) is a widely adopted source of gene functional annotation, including biological process, molecular function and cellular component.[13](#jcmm14696-bib-0013){ref-type="ref"}

2.3. Study population {#jcmm14696-sec-0005}
---------------------

We recruited 471 knee OA patients and 532 healthy controls from the Affiliated Changzhou No. 2 People\'s Hospital of Nanjing Medical University, the Second Affiliated Hospital of Jiaxing University and the Second Affiliated Hospital, Zhejiang University School of Medicine between November 2014 and July 2018. Knee OA was diagnosed in accordance with the clinical and radiographic criteria of the American College of Rheumatology (1987).[14](#jcmm14696-bib-0014){ref-type="ref"} Exclusion criteria for OA patients were as follows: (a) autoimmune disorders, malignant tumour, cardiovascular diseases and liver and kidney dysfunction; (b) history of arthritis; and (c) drug abuse more than 3 months. The healthy controls were selected from the outpatients of the above hospitals during the same period. X‐ray analysis confirmed no evident symptoms of joint pain and the absence of knee OA. Demographic and clinical information (C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), visual analogue score (VAS) and Kellgren‐Lawrence grade) was collected from all participants by using a written questionnaire and reviewing medical records. Individuals who smoked at least one cigarette daily were considered as smokers. Alcohol usage was defined as consumption of at least three alcoholic drinks one week. This study was approved by the Ethics Committees of the above three hospitals and was consistent with the Declaration of Helsinki. Each subject provided written informed consent prior to participation.

2.4. SNP selection process {#jcmm14696-sec-0006}
--------------------------

Selection process was as follows. First, we identified five OA‐related genes (DVL1, WNT16, ITIH5, LRP1 and SFRP1) on the Wnt signalling pathway by reviewing the literature. Second, we found out whether the SNPs on these genes have been studied in the disease. Third, SNPs with minor allele frequency \> 0.5, located in the promoter, exon or 3'‐UTR were selected. In total, five SNPs in Wnt signalling pathway‐related genes were selected, including rs61735963, rs2908004, rs10795550, rs1799986 and rs1127379.

2.5. Genotyping {#jcmm14696-sec-0007}
---------------

Peripheral blood (2 mL) was collected from each subject. Genomic DNA was extracted using a QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instruction. DNA samples were tested for purity and concentration with an ultraviolet spectrophotometer and stored at −20°C. PCR primers were designed on Primer Premier 5.0 (Premier, Pala Alto, CA, USA). PCR amplification was conducted in 25‐μL volumes each containing 1 μL of the DNA template, 2.5 μL of 3 mmol/L dNTPs, 1.0 μL of each primer (10 mmol/L), 2.5 μL of 10× PCR buffer (added with MgCl~2~), 1.0 U of Taq DNA polymerase and ddH~2~O. DNA was denatured at 95°C for 6 minutes, then amplified by 35 PCR cycles (95°C for 30 seconds, 50°C for 1 minutes, 72°C for 30 seconds) and finally extended at 72°C for 10 minutes. PCR products were revealed on 2% agarose gel electrophoresis with ethidium bromide, purified using a DNA purification kit and then genotyped through Sanger sequencing.

2.6. Reverse transcription‐polymerase chain reaction {#jcmm14696-sec-0008}
----------------------------------------------------

Total RNA was isolated from the whole blood from the OA patients and healthy controls using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer\'s instructions. Five genes (DVL1, WNT16, ITIH5, LRP1 and SFRP1) expression were detected by RT‐PCR with Hifair^TM^ first‐strand cDNA synthesis SuperMix and qPCR SYBR Green Master Mix (Yesen, Shanghai, China). Forward and reverse primers used for PCR were as follows: 5\'‐CGTAAAGTGCTGGGGACCTT‐3\', 5\'‐GATCCACGCACTCAGGAACT‐3\' (SFRP1); 5\'‐TCCTCACTAACCAGCTCCGT‐3\', 5\'‐GCGCTCATGTCACTCTTCAC‐3\' (DVL1); 5\'‐CTACAGCTCCCTGCAAACGA‐3\', 5\'‐AGCACCAAGTTATCCCTCGC‐3\' (WNT16); 5\'‐GTCCCTGTGTGTGGGGTC‐3\', 5\'‐ACCCTGAGTCCATCCTGCTC‐3\' (ITIH5); 5\'‐CCGCTCTGATGAGTCTGCTT‐3\', 5\'‐AGTCATTGTCATTGTCGCATCT‐3\' (LRP1); 5\'‐GATGAGATTGGCATGGCTTT‐3\', 5\'‐GTCACCTTCACCGTTCCAGT‐3\' (β‐actin). Statistical analysis used relative quantification, and the 2^−△△CT^ method was used to calculate relative expression.

2.7. Statistical analysis {#jcmm14696-sec-0009}
-------------------------

Continuous variables were expressed as mean ± standard deviation and analysed using Student\'s *t* test or Mann‐Whitney *U* test. Categorical variables were reported as frequency and percentage and analysed using chi‐squared test. The genotype frequencies among controls in line with Hardy‐Weinberg equilibrium (HWE) were investigated through goodness‐of‐fit chi‐squared test. The risk of gene for OA was evaluated by calculating odds ratios (ORs) and 95% confidence intervals (CIs). Stratification analysis was conducted according to sex, age, smoking, alcohol consumption and body mass index (BMI). The effect size of each SNP was investigated using crude ORs. If the SNPs' disease risk was independent, the weighted genetic risk score (GRS) was estimated as the sum of (log OR of SNP) × (number of risk alleles carried by the individual) across five SNPs. The GRS was then divided into quartiles according to the normalized value and calculated by binary logistic regression. All statistical analyses were performed on SAS 9.1.3 (SAS Institute, Cary, NC, USA). *P* \< .05 was considered statistically significant.

3. RESULTS {#jcmm14696-sec-0010}
==========

3.1. Study characteristics {#jcmm14696-sec-0011}
--------------------------

The systematic database searching returned 25 articles, of which 12 articles were excluded, including three duplicates, and nine reviews, meeting reports or unrelated articles. Finally, 13 articles involving 20 genes and 127 SNPs were included for further analysis. The detailed characteristics of the selected studies are presented in Table [1](#jcmm14696-tbl-0001){ref-type="table"}, including 6 case‐control studies, four case‐only studies and three cohort studies. Ten articles were conducted among Caucasians and three among Asians. Twelve of the 127 SNPs were associated with the risk of OA (Table [2](#jcmm14696-tbl-0002){ref-type="table"}). Most of the SNPs were located at the intron region of genes. Seven SNPs (rs12341259, rs851054, rs986690, rs41494349, rs7164503, rs12593365 and rs2908004) decreased and five SNPs (rs2353525, rs409238, rs2615977, rs2707466 and rs2929970) increased the risk of OA.

###### 

Characteristics of included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and year        Type of study         Country       Sample size             Genotyping method   Polymorphism                                                                                                                                                                                                              QAS
  ---------------------- --------------------- ------------- ----------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----
  Loughlin2004           Family case‐control   UK            OA/control\             PCR‐RFLP            TNFAIP6 rs1046668; ITGA6 rs2737085 rs10209072; FRZB rs288326 rs7775                                                                                                                                                       8
                                                             936/760                                                                                                                                                                                                                                                               

  Urano2007              Case‐only             Japan         Spinal OA\              TaqMan              W1SP1 2364A/G                                                                                                                                                                                                             7
                                                             304                                                                                                                                                                                                                                                                   

  Kerkhof2008            Cohort                Netherlands   Hip/knee/hand OA 2507   TaqMan              FRZB rs288326 rs7775; LRP5 Ala1330val; LRP6 lle1062val                                                                                                                                                                    8

  Urano2008              Case‐only             Japan         Spinal OA\              TaqMan              LRP5 Q89R                                                                                                                                                                                                                 7
                                                             357                                                                                                                                                                                                                                                                   

  Valdes2009             Case‐control          UK            Knee/hip OA/control\    PCR                 ANP32A rs7164503                                                                                                                                                                                                          7
                                                             2170/2849                                                                                                                                                                                                                                                             

  Lamas2010              Case‐control          Spain         OA/control\             N/A                 COL10A1 rs11965969                                                                                                                                                                                                        7
                                                             191/283                                                                                                                                                                                                                                                               

  Gao2010                Family cohort         China         Osteoarthritis\         TaqMan              FZRB rs643399 rs409238 rs288324 rs4666865                                                                                                                                                                                 7
                                                             1260                                                                                                                                                                                                                                                                  

  Leijten2012            Cohort                Netherlands   OA\                     N/A                 GREM1 rs1881537 rs921510 rs4779584 rs1258726 rs12593365\                                                                                                                                                                  8
                                                             7142                                        DKK1 rs11636374 rs12905294 rs16959110 rs16959022 rs12593223 rs11071936 rs10318                                                                                                                                            

  Baker‐LePain2012       Case‐control          USA           Hip OA/controls\        PCR                 FRZB (rs288326 rs7775)                                                                                                                                                                                                    9
                                                             451/601                                                                                                                                                                                                                                                               

  Garca‐Ibarbia2013      Case‐only             Spain         Hip fractures/hip OA\   Sequencing          WNT4 (rs7526484 rs2235526 rs10917158)\                                                                                                                                                                                    9
                                                             500/353                                     WNT10A (rs3806557 rs10177996 rs2385199)\                                                                                                                                                                                  
                                                                                                         WNT16 (rs3779381 rs2908004 rs2707471 rs3801385 rs2707466 rs17143305)\                                                                                                                                                     
                                                                                                         SFRP1 (rs3242 rs1127379 rs7820647 rs11786592 rs6651363 rs10109536 rs17652488 rs10958671 rs17574424 rs7832767 rs968427 rs921142)                                                                                           

  Garca‐Ibarbia2013      Case‐control          Spain         Hip/knee OA/control\    TaqMan              WNT1 (rs11610885 rs10878228 rs7397906 rs6581609 rs1900292); WNT10A (rs3806557 rs10177996 rs2385199)\                                                                                                                      10
                                                             680/606                                     WNT16 (rs3779381 rs29008004 rs2707471 rs3801385 rs2707466 rs17143305)\                                                                                                                                                    
                                                                                                         DVL2 (rs2074222 rs222837 rs222836 rs2074216)\                                                                                                                                                                             
                                                                                                         FZD5 (rs3731567 rs35994626)\                                                                                                                                                                                              
                                                                                                         BCL9 (rs666569 rs10793689 rs17160413 rs12081028 rs6659237 rs1546161 rs10793690 rs7523564 rs1015235 rs2353544 rs11240082 rs11240083 rs10900382 rs2353525 rs688325 rs6675828 rs3737843 rs11807878 rs3766512)\               
                                                                                                         SFRP1 (rs3242 rs1127379 rs7820647 rs11786592 rs6651363 rs10109536 rs17652488 rs10958671 rs17574424 rs7832767 rs968427 rs921142)\                                                                                          
                                                                                                         SFRP4 (rs2598116 rs1052981 rs1802074 rs1802073 rs2598115 rs1450856 rs3807192)\                                                                                                                                            
                                                                                                         TCF7L1 (rs3810822 rs2568217 rs2568225 rs11682047 rs11693369 rs2568197 rs2568203 rs2568210 rs4832148 rs12477587 rs17763853 rs7581133 rs11904127 rs6547606 rs10204252 rs17764504 rs7574856 rs4832156 rs6741339 rs11547160   

  Garca‐Ibarbia2017      Case‐only             Spain         Hip OA/knee OA\         TaqMan              WNT16 rs2707466 rs2908004                                                                                                                                                                                                 8
                                                             173/52                                                                                                                                                                                                                                                                

  Fernandez‐Torres2018   Case‐control          Mexico        Knee OA/control\        TaqMan              LRP6 rs12314259; SOST rs851054; FMN2 rs986690; FRZB rs409328; COL11A1 rs265977                                                                                                                                            8
                                                             141/190                                                                                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

John Wiley & Sons, Ltd

###### 

Positive sites on the Wnt signalling pathway‐related genes

  SNP          Gene      Major/minor allele   MAF           Location        Results   Country
  ------------ --------- -------------------- ------------- --------------- --------- -------------
  Rs2353525    BCL9      T/G                  0.4293/1250   Intron          Risk      Spain
  Rs12341259   LRP6      C/T                  0.0094/47     Intron          Protect   Mexico
  Rs851054     SOST      C/A                  0.4441/2224   Intron/3'‐UTR   Protect   Mexico
  Rs986690     FMN2      G/A                  0.3203/1604   Intron          Protect   Mexico
  Rs409238     FRZB      G/A                  0.4301/2154   Intron          Risk      Mexico
  Rs2615977    COL11A1   A/C                  0.2194/1099   Intron          Risk      Mexico
  Rs2707466    WNT16     C/T                  0.4970/2489   Exon            Risk      Spain
  Rs2929970    WISP1     G/A                  0.4441/2224   3'‐UTR          Risk      Japan
  Rs41494349   LRP5      A/G                  0.0200/100    Exon/promoter   Protect   Japan
  Rs7164503    ANP32A    T/C                  0.3816/1911   Intron          Protect   UK
  Rs12593365   GREM1     T/C                  0.2165/1084   Exon            Protect   Netherlands
  Rs2908004    WNT16     G/A                  0.4896/2452   Exon            Protect   Spain

John Wiley & Sons, Ltd

3.2. Bioinformatics analysis {#jcmm14696-sec-0012}
----------------------------

We constructed the PPI network of the Wnt pathway genes associated with OA reported in the literature (Figure [1](#jcmm14696-fig-0001){ref-type="fig"}). Three genes (WNT16, LRP5 and LRP6) were considered as key genes in the PPI module. GO analysis indicated these genes were significantly related to cellular process (biological process), cell part (cellular component) and protein binding (molecular function) (Figure [2](#jcmm14696-fig-0002){ref-type="fig"}).

![The protein interaction network of Wnt/β‐catenin pathway‐related genes](JCMM-23-8246-g001){#jcmm14696-fig-0001}

![Barplot of representative GO analysis of Wnt/β‐catenin pathway‐related genes. A, Biological process; B, cellular component; C, molecular function](JCMM-23-8246-g002){#jcmm14696-fig-0002}

3.3. Clinical parameters of the study population {#jcmm14696-sec-0013}
------------------------------------------------

The OA patients and controls were aged 57.87 and 57.47 years on average respectively (Table [3](#jcmm14696-tbl-0003){ref-type="table"}). About 54% of the participants in the two groups were females. The average BMIs did not differ significantly between groups (*P* = .632). The majority of OA patients were assigned with Kellgren‐Lawrence grade III + IV. Clinical characteristics (eg ESR, CRP, VAS and Lequesnes' index) of patients were also collected to investigate the pathology of OA.

###### 

Patient demographics and risk factors in osteoarthritis

  Variable                  Cases (n = 471)   Controls (n = 532)   *P*
  ------------------------- ----------------- -------------------- ------
  Age (y)                   57.87 ± 8.79      57.47 ± 9.25         .482
  Sex                                                              
  Male                      214 (45.4%)       248 (46.6%)          .708
  Female                    257 (54.6%)       284 (53.4%)          
  BMI                       25.04 ± 3.95      24.92 ± 3.78         .632
  Smoking                                                          
  Yes                       201 (42.7%)       244 (45.9%)          .310
  No                        270 (57.3%)       288 (54.1%)          
  Alcohol                                                          
  Yes                       238 (50.5%)       239 (44.9%)          .076
  No                        233 (49.5%)       293 (55.1%)          
  ESR                       11.52 ± 13.52     --                   --
  CRP                       7.15 ± 15.67      --                   --
  VAS                       7.92 ± 1.25       --                   --
  Lequesnes' index          15.32 ± 1.88      --                   --
  L/R knee OA                                                      
  Left                      252 (53.5%)       --                   --
  Right                     219 (46.5%)       --                   
  Kellgren‐Lawrence grade                                          
  II                        65 (13.8%)        --                   --
  III                       198 (42.0%)       --                   
  IV                        208 (44.2%)       --                   

Abbreviations: BMI, body mass index; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale.

John Wiley & Sons, Ltd

3.4. Wnt pathway‐related genes variant analyses {#jcmm14696-sec-0014}
-----------------------------------------------

The genotype and allele distributions of five SNPs are shown in Table [4](#jcmm14696-tbl-0004){ref-type="table"}. No significant deviation from HWE was found for any SNP in either group. WNT16 rs2908004 polymorphism was associated with a decreased risk of OA in the co‐dominant, recessive, dominant and allelic models. Additionally, the TT genotype versus CC genotype of rs1799986 polymorphism had a 0.49‐fold decreased risk of OA (TT vs. CC: OR 0.49; 95%CI 0.29‐0.83; *P* = .008). Furthermore, the CT + TT genotype significantly increased OA risk (CT + TT vs. CC: OR 0.72; 95%CI 0.56‐0.93; *P* = .011). Similar findings were observed in the dominant and allelic models. Notably, these associations were still significant after adjusting sex and age. No meaningfully or statistically significant associations with OA risk were noted in other polymorphisms.

###### 

Logistic regression analysis of associations between polymorphisms and risk of osteoarthritis

  Genotype         Cases[a](#jcmm14696-note-0005){ref-type="fn"} (n = 471)   Controls[a](#jcmm14696-note-0005){ref-type="fn"} (n = 532)   OR (95% CI)   *P*    OR (95% CI)[b](#jcmm14696-note-0006){ref-type="fn"}   *P* [b](#jcmm14696-note-0006){ref-type="fn"}                          
  ---------------- --------------------------------------------------------- ------------------------------------------------------------ ------------- ------ ----------------------------------------------------- ---------------------------------------------- ---------------------- -----------
  rs2908004 G/A                                                                                                                                                                                                                                                                            
  GG               158                                                       33.6                                                         138           26.0   1.00                                                  --                                             --                     --
  GA               228                                                       48.5                                                         265           49.9   0.75 (0.57‐1.01)                                      0.056                                          0.75 (0.57‐1.01)       0.056
  AA               84                                                        17.9                                                         128           24.1   **0.57 (0.40‐0.82)**                                  **0.002**                                      **0.57 (0.40‐0.82)**   **0.002**
  GA + AA          312                                                       66.4                                                         393           74.0   **0.70 (0.53‐0.91)**                                  **0.009**                                      **0.69 (0.53‐0.91)**   **0.009**
  GG + GA          386                                                       82.1                                                         403           75.9   1.00                                                  --                                             --                     --
  AA               84                                                        17.9                                                         128           24.1   **0.68 (0.50‐0.93)**                                  **0.016**                                      **0.68 (0.50‐0.93)**   **0.015**
  G allele         544                                                       57.9                                                         541           50.9   1.00                                                  --                                             --                     --
  A allele         396                                                       42.1                                                         521           49.1   **0.76 (0.63‐0.90)**                                  **0.002**                                      --                     --
  rs10795550 T/C                                                                                                                                                                                                                                                                           
  TT               285                                                       60.6                                                         305           57.4   1.00                                                  --                                             --                     --
  TC               162                                                       34.5                                                         195           36.7   0.89 (0.69‐1.16)                                      0.404                                          0.90 (0.69‐1.17)       0.418
  CC               23                                                        4.9                                                          31            5.8    0.79 (0.45‐1.39)                                      0.422                                          0.79 (0.45‐1.39)       0.418
  TC + CC          185                                                       39.4                                                         226           42.6   0.88 (0.68‐1.13)                                      0.322                                          0.88 (0.68‐1.14)       0.328
  TT + TC          447                                                       95.1                                                         500           94.2   1.00                                                  --                                             --                     --
  CC               23                                                        4.9                                                          31            5.8    0.83 (0.48‐1.44)                                      0.505                                          0.83 (0.47‐1.44)       0.498
  T allele         732                                                       77.9                                                         805           75.8   1.00                                                  --                                             --                     --
  C allele         208                                                       22.1                                                         257           24.2   0.89 (0.72‐1.10)                                      0.273                                          --                     --
  rs1127379 T/C                                                                                                                                                                                                                                                                            
  TT               120                                                       25.6                                                         146           27.5   1.00                                                  --                                             --                     --
  TC               234                                                       49.9                                                         265           49.9   1.07 (0.80‐1.45)                                      0.639                                          1.08 (0.80‐1.45)       0.624
  CC               115                                                       24.5                                                         120           22.6   1.18 (0.83‐1.67)                                      0.368                                          1.18 (0.83‐1.68)       0.358
  TC + CC          349                                                       74.4                                                         385           72.5   1.11 (0.84‐1.47)                                      0.485                                          1.11 (0.84‐1.47)       0.471
  TT + TC          354                                                       75.5                                                         411           77.4   1.00                                                                                                                         
  CC               115                                                       24.5                                                         120           22.6   1.12 (0.84‐1.50)                                      0.441                                          1.12 (0.84‐1.51)       0.436
  T allele         474                                                       50.5                                                         557           52.4   1.00                                                  --                                             --                     --
  C allele         464                                                       49.5                                                         505           47.6   1.08 (0.91‐1.29)                                      0.392                                          --                     --
  rs61735963 C/T                                                                                                                                                                                                                                                                           
  CC               403                                                       85.7                                                         444           83.6   1.00                                                  --                                             --                     --
  CT               64                                                        13.6                                                         83            15.6   0.85 (0.60‐1.21)                                      0.359                                          0.85 (0.60‐1.21)       0.358
  TT               3                                                         0.6                                                          4             0.8    0.82 (0.18‐3.71)                                      0.801                                          0.82 (0.18‐3.68)       0.793
  CT + TT          67                                                        14.3                                                         87            16.4   0.85 (0.60‐1.20)                                      0.345                                          0.85 (0.60‐1.20)       0.348
  CC + CT          467                                                       99.4                                                         527           99.2   1.00                                                  --                                             --                     --
  TT               3                                                         0.6                                                          4             0.8    0.85 (0.19‐3.80)                                      0.827                                          0.84 (0.19‐3.77)       0.819
  C allele         870                                                       92.6                                                         971           91.4   1.00                                                  --                                             --                     --
  T allele         70                                                        7.4                                                          91            8.6    0.86 (0.62‐1.19)                                      0.357                                          --                     --
  rs1799986 C/T                                                                                                                                                                                                                                                                            
  CC               287                                                       61.1                                                         282           53.1   1.00                                                  --                                             --                     --
  CT               160                                                       34.0                                                         203           38.2   0.77 (0.59‐1.01)                                      0.055                                          0.77 (0.59‐1.01)       0.056
  TT               23                                                        4.9                                                          46            8.7    **0.49 (0.29‐0.83)**                                  **0.008**                                      **0.49 (0.29‐0.83)**   **0.008**
  CT + TT          183                                                       38.9                                                         249           46.9   **0.72 (0.56‐0.93)**                                  **0.011**                                      **0.72 (0.56‐0.93)**   **0.011**
  CC + CT          447                                                       95.1                                                         485           91.3   1.00                                                  --                                             --                     --
  TT               23                                                        4.9                                                          46            8.7    **0.54 (0.32‐0.91)**                                  **0.020**                                      **0.54 (0.32‐0.91)**   **0.021**
  C allele         734                                                       78.1                                                         767           72.2   1.00                                                  --                                             --                     --
  T allele         206                                                       21.9                                                         295           27.8   **0.73 (0.60‐0.90)**                                  **0.003**                                      --                     --

Bold values are statistically significant (*P* \< .05).

The genotyping was successful in 470 cases and 531 controls for rs2908004, rs10795550, rs61735963 and rs1799986; the genotyping was successful in 469 cases and 531 controls for rs1127379.

Adjust for age and sex.

John Wiley & Sons, Ltd

Stratified analyses by sex, age, smoking, drinking and BMI were conducted (Table [5](#jcmm14696-tbl-0005){ref-type="table"}). For rs2908004, the decreased effect was more evident in the subgroups of females, age \< 60 and BMI ≥ 25. In addition, the decreased association between LRP1 rs1799986 polymorphism was stronger in the subgroups of males, smokers, non‐drinkers, age \< 60 and BMI ≥ 25. Subsequently, we investigated the possible association between the two above polymorphisms and clinical characteristics (CRP, ESR, VAS, Lequesnes' index and K‐L grade) of OA patients (Table [6](#jcmm14696-tbl-0006){ref-type="table"}). GG + AA genotype carriers of rs2908004 polymorphism had lower CRP expression and K‐L grade compared to the GG genotype. For rs1799986, the TT genotype was more frequent in the group of VAS ≥ 6 versus VAS \< 6.

###### 

Stratified analyses between rs2908004/rs1799986 polymorphisms and the risk of osteoarthritis

  Variable   Case/control   Heterozygous model   Homozygous model   Recessive model               Dominant model                                              
  ---------- -------------- -------------------- ------------------ ----------------------------- ----------------------------- ----------------------------- -----------------------------
  Sex                                                                                                                                                         
  Male       69/71          108/121              36/56              0.93 (0.61‐1.41); 0.721       0.66 (0.39‐1.13); 0.129       0.69 (0.44‐1.11); 0.124       0.84 (0.57‐1.25); 0.397
  Female     89/67          120/144              48/72              **0.63 (0.42‐0.94); 0.022**   **0.50 (0.31‐0.81); 0.005**   0.67 (0.45‐1.02); 0.060       **0.59 (0.40‐0.85); 0.005**
  Smoking                                                                                                                                                     
  Yes        71/69          104/121              26/53              0.84 (0.55‐1.29); 0.426       **0.48 (0.27‐0.85); 0.012**   **0.53 (0.32‐0.88); 0.015**   0.73 (0.49‐1.09); 0.125
  No         87/69          124/144              58/75              0.68 (0.46‐1.02); 0.060       **0.61 (0.39‐0.98); 0.040**   0.78 (0.53‐1.16); 0.216       **0.66 (0.45‐0.96); 0.028**
  Alcohol                                                                                                                                                     
  Yes        76/62          111/124              45/53              0.68 (0.45‐1.04); 0.073       0.64 (0.38‐1.08); 0.093       0.81 (0.52‐1.27); 0.366       **0.67 (0.45‐0.99); 0.047**
  No         82/76          117/141              39/75              0.83 (0.56‐1.24); 0.362       **0.52 (0.32‐0.86); 0.011**   **0.59 (0.38‐0.90); 0.015**   0.72 (0.49‐1.06); 0.092
  Age (y)                                                                                                                                                     
  \<60       97/80          123/157              54/72              **0.65 (0.45‐0.95); 0.026**   **0.62 (0.39‐0.98); 0.041**   0.80 (0.54‐1.20); 0.284       **0.64 (0.45‐0.91); 0.014**
  ≥60        61/58          105/108              30/56              0.92 (0.59‐1.45); 0.731       **0.51 (0.29‐0.90); 0.021**   **0.54 (0.33‐0.88); 0.013**   0.78 (0.51‐1.20); 0.259
  BMI                                                                                                                                                         
  \<25       74/66          119/139              45/61              0.77 (0.51‐1.16); 0.212       0.66 (0.40‐1.09); 0.107       0.78 (0.51‐1.20); 0.260       0.74 (0.50‐1.09); 0.123
  ≥25        84/72          109/126              39/67              0.74 (0.49‐1.11); 0.149       **0.50 (0.30‐0.83); 0.007**   **0.60 (0.38‐0.93); 0.022**   **0.66 (0.45‐0.96); 0.031**

  Rs1799986   CC        CT       TT      CT vs. CC                     TT vs.CC                      TT vs. CT + CC                TT + CT vs.CC
  ----------- --------- -------- ------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  Sex                                                                                                                              
  Male        123/127   79/94    11/26   0.86 (0.58‐1.27); 0.450       **0.43 (0.21‐0.92); 0.028**   **0.46 (0.22‐0.96); 0.038**   0.77 (0.53‐1.11); 0.162
  Female      164/155   81/109   12/20   0.70 (0.49‐1.01); 0.056       0.57 (0.27‐1.20); 0.138       0.65 (0.31‐1.35); 0.246       **0.68 (0.48‐0.96); 0.030**
  Smoking                                                                                                                          
  Yes         115/134   75/86    10/23   **0.63 (0.44‐0.89); 0.010**   **0.49 (0.24‐0.99); 0.048**   0.50 (0.3‐1.08); 0.078        0.90 (0.62‐1.32); 0.592
  No          172/148   85/117   13/23   1.01 (0.68‐1.50); 0.966       0.50 (0.23‐1.10); 0.086       0.58 (0.29‐1.18); 0.132       **0.60 (0.43‐0.85); 0.003**
  Alcohol                                                                                                                          
  Yes         148/128   78/94    12/17   0.71 (0.49‐1.04); 0.082       0.61 (0.28‐1.32); 0.206       0.69 (0.32‐1.48); 0.340       0.70 (0.48‐1.00); 0.052
  No          139/154   82/109   11/29   0.83 (0.58‐1.20); 0.331       **0.42 (0.20‐0.87); 0.020**   **0.45 (0.22‐0.92); 0.030**   0.75 (0.53‐1.06); 0.101
  Age (y)                                                                                                                          
  \<60        174/164   88/121   13/24   **0.68 (0.48‐0.97); 0.031**   0.51 (0.25‐1.03); 0.060       0.59 (0.29‐1.18); 0.134       **0.65 (0.47‐0.91); 0.012**
  ≥60         113/118   72/82    10/22   0.92 (0.61‐1.38); 0.677       0.48 (0.22‐1.05); 0.065       0.49 (0.23‐1.07); 0.072       0.82 (0.56‐1.21); 0.326
  BMI                                                                                                                              
  \<25        142/136   84/111   12/19   0.72 (0.50‐1.04); 0.080       0.60 (0.28‐1.28); 0.188       0.69 (0.33‐1.45); 0.324       0.70 (0.49‐1.00); 0.050
  ≥25         145/146   76/92    11/27   0.83 (0.57‐1.22); 0.343       **0.41 (0.20‐0.86); 0.018**   **0.44 (0.21‐0.91); 0.026**   0.74 (0.51‐1.06); 0.095

Bold values are statistically significant (*P* \< .05).

John Wiley & Sons, Ltd

###### 

The associations between rs2908004/rs1799986 polymorphism and clinical characteristics of osteoarthritis

  Characteristics         Genotype distributions                                                             
  ----------------------- ------------------------ ---------------------------- ---------------------------- ----------------------------
  ESR                                                                                                        
  ≥10/＜10                61/97                    97/131                       32/52                        129/183
  OR (95%CI); *P*‐value   1.0 (reference)          1.18 (0.78‐1.78); .439       0.98 (0.57‐1.69); .938       1.12 (0.76‐1.65); .568
  CRP                                                                                                        
  ≥25/\<25                15/143                   10/218                       3/81                         13/299
  OR (95%CI); *P*‐value   1.0 (reference)          0.44 (0.19‐1.00); .054       0.35 (0.10‐1.26); .095       **0.41 (0.19‐0.89); .021**
  K‐L grade                                                                                                  
  Ⅲ + Ⅳ/Ⅰ + Ⅱ             133/25                   170/58                       59/25                        229/83
  OR (95%CI); *P*‐value   1.0 (reference)          **0.55 (0.33‐0.93); .024**   **0.44 (0.24‐0.84); .011**   **0.52 (0.32‐0.85); .009**
  VAS                                                                                                        
  ≥6/＜6                  151/7                    213/15                       77/7                         290/22
  OR (95%CI); *P*‐value   1.0 (reference)          0.66 (0.26‐1.65); .371       0.51 (0.17‐1.51); .216       0.61 (0.26‐1.46); .265
  Lequesnes' index                                                                                           
  ≥12/\<12                153/5                    218/10                       81/3                         299/13
  OR (95%CI); *P*‐value   1.0 (reference)          0.71 (0.24‐2.13); .542       0.88 (0.21‐3.79); .866       0.75 (0.26‐2.15); .593

  Rs1799986               CC                CT                           TT                           CT + TT
  ----------------------- ----------------- ---------------------------- ---------------------------- ----------------------------
  ESR                                                                                                 
  ≥10/＜10                111/176           70/90                        8/15                         78/105
  OR (95%CI); *P*‐value   1.0 (reference)   1.23 (0.83‐1.83); .295       0.85 (0.35‐2.06); .712       1.18 (0.81‐1.72); .395
  CRP                                                                                                 
  ≥25/\<25                17/270            9/151                        1/22                         10/173
  OR (95%CI); *P*‐value   1.0 (reference)   0.95 (0.41‐2.18); .897       0.72 (0.09‐5.68); 0.756      0.92 (0.41‐2.05); .835
  K‐L grade                                                                                           
  Ⅲ + Ⅳ/Ⅰ + Ⅱ             250/37            135/25                       20/3                         155/28
  OR (95%CI); *P*‐value   1.0 (reference)   0.80 (0.46‐1.38); .423       0.99 (0.28‐3.48); .983       0.82 (0.48‐1.39); .461
  VAS                                                                                                 
  ≥6/\<6                  274/13            144/16                       19/4                         163/20
  OR (95%CI); *P*‐value   1.0 (reference)   **0.43 (0.20‐0.91); .024**   **0.23 (0.07‐0.76); .009**   **0.39 (0.19‐0.80); .008**
  Lequesnes' index                                                                                    
  ≥12/\<12                277/10            152/8                        22/1                         174/9
  OR (95%CI); *P*‐value   1.0 (reference)   0.69 (0.27‐1.77); .435       0.79 (0.10‐6.49); .829       0.70 (0.28‐1.75); .442

Bold values are statistically significant (*P* \< .05).

John Wiley & Sons, Ltd

Weighted GRS revealed that individuals in the third/second versus the first quartile had a lower risk of developing OA (Table [7](#jcmm14696-tbl-0007){ref-type="table"}). This relationship remained true after adjusting for sex and age.

###### 

The association of genetic risk score of Wnt signalling pathway‐related genes with risk of osteoarthritis

  Variable              Case (n = 471)   Control (n = 532)   OR (95% CI)            *P* value   Adjusted OR (95% CI)   *P* value
  --------------------- ---------------- ------------------- ---------------------- ----------- ---------------------- -----------
  First (−0.5,0)        311 (66.9%)      287 (53.9%)         1                                  1                       
  Second (−1.0, −0.5)   149 (31.6%)      216 (40.6%)         **0.64 (0.49,0.83)**   **.001**    **0.63 (0.49,0.82)**   **.001**
  Third (−1.5, −1.0)    5 (1.1%)         24 (4.5%)           **0.19 (0.07,0.51)**   **.001**    **0.19 (0.07,0.51)**   **.001**

The genotyping was successful in 465 cases and 527 controls. Adjusted for sex and age. Bold values are statistically significant (*P* \< .05).

John Wiley & Sons, Ltd

The mRNA expression of WNT16 or LRP1 was regulated by the genotypes of rs2908004 or rs1799986 polymorphism (Figure [3](#jcmm14696-fig-0003){ref-type="fig"}). Our results indicated that WNT16 and LRP1 were upregulated in OA compared to that in healthy controls. There existed a significant difference in the mRNA expression for rs2908004 or rs1799986 polymorphism (*P* \< .05).

![The mRNA expression by the genotypes of two polymorphisms among cases and controls. (A) WNT16 rs2908004 polymorphism; (B) LRP1 rs1799986 polymorphism](JCMM-23-8246-g003){#jcmm14696-fig-0003}

4. DISCUSSION {#jcmm14696-sec-0015}
=============

Two polymorphisms (rs2908004 and rs1799986) correlated with a decreased risk of OA, while no significant association was found between other polymorphisms (rs61735963, rs10795550 or rs1127379) and OA risk. Individuals with lower GRS had a lower risk of developing OA. In addition, rs2908004 or rs1799986 polymorphism reduces the expression of WNT16 or LRP1.

β‐catenin‐dependent canonical and independent non‐canonical Wnt signalling pathways play multiple roles in regulating the cartilage development, growth and maintenance in animal models.[15](#jcmm14696-bib-0015){ref-type="ref"} Alterations in genes associated with Wnt/β‐catenin signalling were suggested as susceptibility factors for OA development.[16](#jcmm14696-bib-0016){ref-type="ref"} Some SNPs of Wnt‐related genes influence the genetic predisposition to OA. Therefore, 13 studies changed their focus to the association of polymorphisms in pathway‐related genes with risk of OA. Careful reviewing suggests these 13 articles involved 20 genes and 127 SNPs. Twelve of the 127 SNPs were associated with OA among Caucasians. However, no study uncovered any significant association between these SNPs and OA risk among Asians.

As reported, WNT16 supported the homeostasis of progenitor cells in OA, while WNT16‐deficient mice developed more severe OA with lubricin downregulation and increased chondrocyte apoptosis.[17](#jcmm14696-bib-0017){ref-type="ref"} The expression of inter‐alpha inhibitor H5 (ITIH5) differed significantly between OA synovial tissues and healthy tissues.[18](#jcmm14696-bib-0018){ref-type="ref"} Lipoprotein receptor‐related protein 1 (LRP1) could inhibit tumour necrosis factor (TNF)‐α‐induced apoptosis and inflammation in chondrocytes.[19](#jcmm14696-bib-0019){ref-type="ref"} The reduced expression of secreted frizzled related protein 1 (SFRP1) increased the activation of the Wnt/β‐catenin signalling and rendered the articular cartilage prone to premature.[20](#jcmm14696-bib-0020){ref-type="ref"} We selected five SNPs (DVL1 rs61735963, WNT16 rs2908004, ITIH5 rs10795550, LRP1 rs1799986 and SFRP1 rs1127379) and investigated their association with OA risk in a Chinese population. Two SNPs (WNT16 rs2908004 and LRP1 rs1799986) were reported.[21](#jcmm14696-bib-0021){ref-type="ref"}, [22](#jcmm14696-bib-0022){ref-type="ref"} WNT16 could influence bone mineral density (BMD), cortical bone thickness and osteoporotic fracture risk.[23](#jcmm14696-bib-0023){ref-type="ref"} Radiographic OA was associated with high BMD and increased rate of bone loss.[24](#jcmm14696-bib-0024){ref-type="ref"} WNT16 rs2908004 polymorphism was associated with different OA phenotypes (atrophic or hypertrophic).[21](#jcmm14696-bib-0021){ref-type="ref"} Our results indicate WNT16 rs2908004 polymorphism conferred susceptibility to OA by comparing genotype and allele distribution between cases and controls. LRP1 dictates physiological and pathological catabolism of aggrecan by regulating extracellular activity of ADAMTS5.[25](#jcmm14696-bib-0025){ref-type="ref"} Inhibited shedding of low‐density LRP1 reversed the cartilage matrix degradation in OA.[26](#jcmm14696-bib-0026){ref-type="ref"} The role of LRP1 rs1799986 polymorphism was studied in various diseases, including cardiovascular disease [27](#jcmm14696-bib-0027){ref-type="ref"} and Alzheimer\'s disease (AD).[22](#jcmm14696-bib-0022){ref-type="ref"} LRP1 rs1799986 polymorphism was associated with lower risk of AD among Asians and could reduce risk of late onset of AD, as revealed by a meta‐analysis containing 6455 AD cases and 6304 controls.[22](#jcmm14696-bib-0022){ref-type="ref"} However, little is known about their association with OA susceptibility. We found TT genotype or T allele significantly increased risk of OA in a Chinese population. Furthermore, the mRNA expression of WNT16 or LRP1 in mutant genotype carriers was significantly lower than that of wild genotype carriers. We hypothesized that rs2908004 or rs1799986 polymorphism conferred susceptibility to OA by influencing its production and function.

Several limitations of this study should be addressed. First, other confounders (eg occupation and diet) were not considered. Second, we recruited cases and controls only from hospitals, which may lead to selection bias during the collection process. Third, we may obtain the false‐negative or false‐positive results due to limited sample size. Fourth, two positive SNPs in exons may affect the protein expression, leading to OA susceptibility. However, this was not verified by experiments.

This study confirms that WNT16 rs2908004 polymorphism plays a protective role in the pathology of knee OA. Additionally, LRP1 rs1799986 polymorphism is associated with a decreased risk of OA. Nevertheless, larger‐size and well‐designed case‐control studies among other populations are warranted to identify the association between these polymorphisms and knee OA susceptibility.
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